# Roy S. Herbst

Source: https://onco.cc/people/roy-herbst/  
OnCo record `roy-herbst` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial.

## Summary

Roy Herbst (Yale Cancer Center) led KEYNOTE-010, the trial that established pembrolizumab for previously treated PD-L1-positive NSCLC, and was co-principal investigator of ADAURA, which showed adjuvant osimertinib dramatically cuts recurrence and improves survival in resected EGFR-mutant lung cancer. He co-led the Lung-MAP master protocol and the early atezolizumab biomarker work. His current focus is adjuvant and neoadjuvant targeted therapy.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lung; immunotherapy; adjuvant
- Role: Deputy Director and Chief of Medical Oncology, Yale Cancer Center
- Specialisms: Lung cancer immunotherapy; Adjuvant targeted therapy; Early drug development; Biomarkers

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Roy_S._Herbst
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Herbst%20RS%5BAuthor%5D%20lung%20pembrolizumab%20OR%20osimertinib

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high non-small-cell lung cancer without a driver mutation](https://onco.cc/cancers/pdl1-high-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Osimertinib](https://onco.cc/drugs/osimertinib/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Dartmouth Cancer Center](https://onco.cc/institutions/dartmouth-cancer-center/), [Yale Cancer Center / Smilow Cancer Hospital](https://onco.cc/institutions/yale-cancer-center/)
- trials: [ADAURA](https://onco.cc/trials/adaura/), [Lung-MAP (SWOG S1400 and S1900)](https://onco.cc/trials/lung-map/)
- key papers: [ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer](https://onco.cc/key-papers/paper-adaura-8-year-os-jto-2026/), [ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-adaura-nejm-2020/), [Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC](https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/), [KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer](https://onco.cc/key-papers/paper-keynote-010-lancet-2016/)
- terms: [Master protocol (platform, basket and umbrella trials)](https://onco.cc/terms/master-protocol/)

---
JSON: https://onco.cc/api/v1/entities/roy-herbst.json